AriBio presents topline results for AR1001 in early Alzheimer’s disease

16/11/2026

On 16 November, AriBio, a biotechnology company developing therapies for neurodegenerative diseases, presented topline results from its global Phase III POLARIS-AD trial of AR1001, an investigational oral therapy for early Alzheimer’s disease (AD), at the Clinical Trials on Alzheimer’s Disease conference in Boston, US.

POLARIS-AD is a global, randomised, double-blind and placebo-controlled Phase III clinical trial evaluating the efficacy and safety of AR1001 in people with early AD. The study enrolled 1,535 participants in 13 countries including countries in Europe. Participants were randomised to receive either once-daily oral AR1001 or placebo for 52 weeks. The primary endpoint was the change from baseline to Week 52 in the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a measure of cognitive and functional impairment evaluated in two prespecified primary populations: the overall population and the monotherapy population. The latter comprised participants who were not receiving an acetylcholinesterase inhibitor or memantine at baseline.

The trial did not meet its primary efficacy objective in the overall population (n=1,535). The treatment difference on the CDR-SB was −0.11 points compared with placebo, numerically favouring AR1001 but not reaching statistical significance. However, the study met its primary efficacy objective in the prespecified monotherapy population (n=604). In this group, AR1001 demonstrated a statistically significant treatment difference of −0.44 points versus placebo on the CDR-SB at Week 52, corresponding to a 31% slowing of clinical decline.  Secondary cognitive and functional measures numerically favoured AR1001 in both populations, with larger effects observed in the monotherapy population.

The company plans to present further analyses at future conferences and discuss the results with the US Food and Drug Administration.

https://www.biospace.com/press-releases/aribios-oral-ar1001-meets-primary-efficacy-objective-in-prespecified-monotherapy-population-in-phase-3-polaris-ad-trial